The post claims Moderna and Merck’s personalized mRNA cancer treatment succeeded in Phase 3. It says the approach compares tumor DNA with healthy DNA and uses AI to help identify mutations most likely to trigger an immune response.

The numerical results it cites come from an earlier Phase 2 trial that followed patients with surgically removed high-risk melanoma for five years: 68.8% remained cancer-free, compared with 49.1% on Keytruda alone. The post also cites a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death in that earlier trial.